© 1995 American Heart Association, Inc.
Articles |
Inhibition of Nitric Oxide Synthesis Causes Myocardial Ischemia in Endotoxemic Rats
From the Department of Surgery (J.A.M.A., H.A.B.), University Hospital Rotterdam (Netherlands) and the Department of Anesthesiology (J.A.M.A., C.I.), Academic Medical Center, Amsterdam, Netherlands.
Correspondence to C. Ince, PhD, Department of Anesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract Inhibitors of nitric oxide (NO) synthesis have been used in the treatment of septic and endotoxic shock. However, several studies question the beneficial effect of inhibiting NO production in sepsis and endotoxemia. We have investigated the effect of inhibition of NO synthesis after endotoxemia in the isolated perfused rat heart. In hearts from endotoxin-treated animals, coronary flow was elevated 64% and oxygen consumption was elevated 20% compared with control hearts. NADH fluorescence imaging was used as an indicator of regional hypoperfusion. A homogeneous low-surface NADH fluorescence, indicative of adequate tissue perfusion, was observed in both control and endotoxin-treated hearts. The increase in coronary flow and oxygen consumption could only partially be prevented by pretreatment of the animals with dexamethasone. Addition of N
-nitro-L-arginine (NNLA), an
inhibitor of NO synthesis, to the perfusion medium eliminated
differences in coronary flow and oxygen consumption between normal and
endotoxin-treated hearts. However, NADH surface fluorescence images of
endotoxin-treated hearts after NNLA revealed areas of high
fluorescence, indicating local ischemia, whereas the control hearts
remained without signs of ischemia. The ischemic areas were
present at various perfusion pressures and disappeared after the
infusion of L-arginine, the natural precursor of NO, or the
exogenous NO donor sodium nitroprusside. Methylene blue (MB), an
inhibitor of soluble guanylate cyclase, the effector enzyme of NO, also
eliminated differences in coronary flow and produced similar areas of
local myocardial ischemia in endotoxin-treated hearts but not in
control hearts. Reducing coronary flow by direct vasoconstriction with
vasopressin resulted in similar patterns of myocardial ischemia as with
NNLA and MB. Our results suggest that the coronary vasodilation in the
isolated rat heart after endotoxemia is caused by an increased release
of NO. Coronary flow reduction with NNLA, MB, or direct
vasoconstriction with vasopressin causes local areas of myocardial
ischemia in endotoxin-treated hearts but not in untreated hearts. These
data suggest that endotoxemia promotes myocardial ischemia in
vulnerable areas of the heart after inhibition of the NO pathway or
direct vasoconstriction.
Key Words: nitric oxide • sepsis • endotoxemia • myocardial ischemia • NADH fluorescence
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Sepsis remains an important cause of mortality, especially when accompanied by shock or multiple organ failure, despite advances in antibiotic and vasopressant therapy.1 The initial cardiovascular changes observed during the hyperdynamic septic state are often characterized by profound vasodilation with normal to high cardiac output, low systemic vascular resistance, and severe hypotension.2 Persistent hypotension with low vascular resistance refractory to vasopressor therapy is present in
50% of the patients who die of septic
shock.2 3 By promoting the release of cytokines and other
mediators, bacterial lipopolysaccharide (LPS [endotoxin]) initiates
many of the cardiovascular changes seen during sepsis in animals and in
humans.4 5 Recent evidence suggests that a massive release of nitric oxide (NO), a very potent endogenous vasodilator, causes much of the vascular relaxation and hypotension of sepsis and endotoxemia.6 7 8 NO is formed from L-arginine by the constitutive NO synthase present in the vascular endothelium and stimulates the enzyme-soluble guanylate cyclase (GC) in the smooth muscle cell, which converts GTP to cGMP, resulting in vascular relaxation. Under physiological conditions, NO plays an important role in the regulation of blood pressure and tissue perfusion. In sepsis and endotoxemia, an inducible form of NO synthase, located in vascular smooth muscle, is formed; this process leads to a massive release of NO, resulting in profound vasodilation.6 The induction of this inducible type of NO synthase can be prevented by pretreatment with glucocorticoids, such as dexamethasone.7 8
In the coronary vessels, NO plays a role in the regulation of myocardial blood flow.9 10 11 12 13 In human septic shock, inappropriately high coronary flow with decreased oxygen extraction has been reported, closely mimicking the peripheral circulatory anomalies of vascular relaxation.14 15 This pattern of disordered coronary flow regulation may be due to the release of a putative vasodilator substance such as NO.8 16
Methylated or nitro-substituted analogues of L-arginine competitively inhibit the formation of NO from L-arginine by NO synthase.17 18 Furthermore, at the end of the NO pathway, the effect of NO can be inhibited by methylene blue (MB), which inhibits the enzyme-soluble GC in the vascular smooth muscle cell.19 It has been suggested that such inhibitors have therapeutic value in the treatment of septic shock, since hypotension is corrected after the administration of these L-arginine analogues and MB.20 21 22 23 However, complete inhibition of NO formation has been shown to increase mortality in endotoxemic animals.24 25 26 Also, many investigators have reported reductions in cardiac output after the inhibition of NO production.21 22 23 24 25 27 Combined with the increased vascular resistance seen after the inhibition of NO formation, such reductions in cardiac output may compromise myocardial and tissue perfusion even further. Decreased coronary flow causing myocardial ischemia has been hypothesized to contribute to the fall in cardiac output seen after the administration of inhibitors of NO synthesis during sepsis and endotoxemia; however, this has never been shown directly.25 28
In the present study, we investigated the effect of
N-nitro-L-arginine
(NNLA)18 and MB19 on myocardial metabolism
and coronary flow in hearts of normal and endotoxin-treated rats by use
of a Langendorff heart preparation. To identify any inadequacies in
oxygen supply causing myocardial ischemia in the perfused hearts, we
used the fluorescence properties of reduced pyridine nucleotide (NADH),
an indicator of mitochondrial respiration.29 30 We used
this technique recently to visualize the existence of microcirculatory
units vulnerable to ischemia in the isolated rat heart.29
In the present study, we hypothesize that such units might be
susceptible for ischemia during endotoxemia when the NO pathway is
inhibited.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Experimental Setup
The protocol was approved by the animal ethics board. Male Wistar rats (300 to 360 g) received either 0.7 mg/kg body wt Escherichia coli endotoxin (LPS, 0127:B8, Sigma Chemical Co) or saline by intraperitoneal injection 12 hours before the initiation of the experiments. Control and endotoxin-treated animals were used for in vivo measurement of blood pressure and heart rate. After anesthesia with pentobarbital (50 mg/kg body wt IP), the right carotid artery was cannulated, and blood pressure was measured by a pressure transducer (Hewlett Packard 8805B corner amplifier) in control and endotoxemic rats.
Animals to be used for isolated perfusion of the heart were anesthetized with ether, and rectal temperature was measured. These animals were heparinized (0.5 mL, 100 IU), and 1 mL of blood was withdrawn from the descending aorta. To assess the adequacy of endotoxin administration, collected blood samples were analyzed for lactate by using an enzymatic and colorimetric procedure.31 For indirect determination of global NO release, measurement of plasma nitrite and nitrate, the stable end products of NO oxidation, was performed by use of an automated procedure based on the Griess reaction.32 The hearts were removed, immediately cooled in ice-cold perfusion medium, and rapidly arranged for constant-pressure perfusion at 37°C according to the Langendorff technique. The perfusion medium consisted of (mmol/L) NaCl 128, KCl 4.7, MgCl2 1, NaH2PO4 0.4, NaHCO3 20.2, CaCl2 1.3, glucose 5.0, and pyruvic acid 2.0 and was oxygenated with 95% O2/5% CO2. All hearts were continuously paced at 5 Hz. To minimize metabolic demand, the left ventricle was drained by a cannula in the apex so that no external work was performed. Flow rates (expressed as milliliters per minute per gram of ventricular wet weight) were measured by an electromagnetic flow probe (Skalar-Medical) in the aortic perfusion line. For the determination of effluent oxygen pressure, the right pulmonary artery was cannulated, and a constant fraction of the coronary effluent was led along a Clark-type electrode (YSI biological oxygen monitor, model 5300, Yellow Springs Instruments). The coronary influent was similarly monitored for oxygen pressure via a side arm of the aortic cannula. Oxygen consumption (in micromoles per minute per gram of ventricular wet weight) was calculated from the product of the influent-effluent concentration difference and coronary flow by using the Bunsen solubility coefficient of oxygen in Krebs-Henseleit buffer (22.7 µL O2/mL per atmosphere at 37°C).
NADH Videofluorometry
NADH is a key intermediate in the transfer of reducing
equivalents from metabolic substrates in the cytosol to oxygen in the
mitochondria in the myocardial cells. During hypoxia, less NADH is
oxidized to NAD+, leading to the accumulation of
NADH. When excited with light at 365 nm, NADH, unlike
NAD+, emits fluorescence light at wavelengths
centered around 475 nm. Therefore, hypoxic regions will appear as areas
of high fluorescence on the surface of the heart. NADH surface
fluorescence provides a sensitive method for visualizing any regional
inadequacies in oxygen supply and incipient myocardial ischemia. NADH
videofluoroscopy allows on-line evaluation of spatial heterogeneity in
hypoxia not detected by global parameters of flow, pressure, and
metabolites. NADH surface fluorescence imaging was performed by
excitation of 1 cm2 of the left ventricle of the
Langendorff-perfused rat heart with light of 360 nm and by measurement
of the emitted fluorescence (460 to 490 nm) by use of an
image-intensified charge-coupled device (CCD) videocamera as described
previously.30 Fluorescence images were recorded on a
videorecorder and computer-analyzed off-line. A subtraction routine was
used in all pictures to enhance contrast.
Experimental Protocol
Perfusion pressure is an important determinant of both oxygen
delivery and oxygen consumption in the isolated Langendorff-perfused
rat heart.33 Therefore, we investigated myocardial
metabolism over a range of perfusion pressures in eight control and
eight endotoxin-treated hearts. Hearts were perfused for a total of 130
minutes. After a period of 30 minutes, which allowed coronary flow to
stabilize at 60 mm Hg, perfusion pressure was first lowered to 20
mm Hg and subsequently increased by stepwise changes in perfusion
pressure of 10 mm Hg at 3-minute intervals to a maximum of 100 mm Hg.
At the end of this series of pressure changes, perfusion pressure was
set at the initial value of 60 mm Hg. When the flow was stable, the
perfusion medium was switched to one containing NNLA in a concentration
of 100 µmol/L. After a 30-minute interval, when a new steady state
was achieved, the stepwise changes in perfusion pressure were repeated
once again. In three hearts, the effects of either
L-arginine (100 µmol/L), the precursor of NO
production,6 or nitroprusside (10 µmol/L), a
nitrovasodilator that acts as an exogenous NO donor,34
were studied after 30 minutes of NNLA. To study the effect of
inhibition of soluble GC, the effector enzyme of NO, we used MB in four
control and four endotoxin-treated hearts. MB was used at a
concentration of 5 µmol/L since higher concentrations (>20 µmol/L)
caused a paradoxical increase in coronary flow in control hearts,
probably attributable to nonspecific toxic effects.35 To
see whether the effect of direct vasoconstriction was different from
the effect of inhibition of NO metabolism, in three separate hearts we
switched to vasopressin, a direct smooth muscle vasoconstrictor, at a
concentration of 1 nmol/L to reach approximately the same reduction
in flow as did NNLA.
The LPS-stimulated induction of NO synthase can be prevented by pretreatment with dexamethasone without affecting NO release of the constitutive enzyme.7 8 To investigate the effect of dexamethasone pretreatment, five rats were injected with dexamethasone (4 mg/kg IV) 90 minutes before LPS infusion compared with three rats in the control group, which received only dexamethasone in combination with saline.
Histological examination by light microscopy was performed after fixation with 10% formaldehyde and hematoxylin/eosin staining to assess whether histopathological differences were present between control and endotoxin-treated hearts.
Chemicals
NNLA, MB, arginine vasopressin, and dexamethasone were obtained
from Sigma. All the other chemicals were obtained from Merck.
Statistics
All values are expressed as mean±SD. Student's
t test for group comparisons or paired t test
where appropriate was used to statistically compare values. To test
whether drug effects were perfusion-pressure dependent, we used
ANCOVA. A value of P<.05 was taken as statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Effects of Endotoxin Administration
Although most animals of the endotoxin-treated group showed signs of lethargy, all animals survived. As shown in the Table
, endotoxin-treated animals showed elevated rectal
temperature, decreased mean arterial blood pressure, increased heart
rate, and increased plasma levels of lactate. Values of serum nitrate
plus nitrite
(NO2-+NO3-) were
elevated in endotoxin-treated animals, indicating increased systemic
release of NO (Table).
|
Histological examination of the hearts after perfusion revealed no signs of capillary thrombosis, leukocyte infiltration, intracellular edema, or tissue damage in control (n=3) or endotoxin-treated (n=3) hearts.
Effect of Endotoxin and Dexamethasone Pretreatment on Coronary
Flow, Effluent PO2, and Oxygen
Consumption
In steady state conditions at a perfusion pressure of 60 mm Hg,
coronary flow was elevated 64% in endotoxin-treated hearts (n=8) (from
9.2±0.6 to 15.0±1.6 mL/min per gram wet weight, Fig 1a), and oxygen consumption was elevated 20% (from
4.0±0.2 to 4.8±0.3 µmol/min per gram wet weight, Fig 1c) compared
with control hearts (n=8). Since the relative rise in coronary flow was
greater than the rise in oxygen consumption, this was accompanied by a
rise in coronary effluent PO2 (from 374±20 to
463±37 mm Hg, Fig 1b). To see whether increased coronary flow could
be prevented with glucocorticoids, we pretreated rats (n=5) with
dexamethasone 90 minutes before the injection of endotoxin.
Dexamethasone pretreatment could only partially prevent the increase in
coronary flow and oxygen consumption in the endotoxin-treated hearts
(11.3±1.9 mL/min per gram and 4.3±0.3 µmol/min per gram,
respectively; Fig 1). Dexamethasone pretreatment was without effect on
coronary flow and oxygen consumption in control hearts (n=3) (8.9±0.7
mL/min per gram and 4.0±0.3 µmol/min per gram, respectively;
P=NS).
|
Effect of Perfusion Pressure on Coronary Flow, Effluent
PO2, Oxygen Consumption, and Mean NADH
Fluorescence
During perfusion at different pressures ranging from 20 to 100
mm Hg, coronary flow (Fig 2a) and oxygen consumption
(Fig 2c) were significantly raised in hearts from endotoxic animals at
perfusion pressures of >20 mm Hg. Decreased oxygen extraction
resulted in a rise of coronary effluent PO2
(Fig 2b). Mean NADH surface fluorescence was not significantly
different between the control and endotoxin-treated hearts for all
perfusion pressures. Signs of local ischemia, detected as small areas
of high fluorescence and a rise of mean NADH surface fluorescence, were
only present at a perfusion pressure of 20 mm Hg. At higher
perfusion pressures, a homogeneous image with low NADH fluorescence
intensity was seen in both groups (Fig 5a and 5c).
|
) and
endotoxin-treated (
) rat hearts. Control (
) and
endotoxin-treated (
) hearts are shown after inhibition of nitric
oxide synthesis with 100 µmol/L
N
|
Effect of Inhibiting NO Synthesis With NNLA on Coronary Flow,
Effluent PO2, and Oxygen
Consumption
Fig 3 shows two representative tracings of
the response in time of coronary flow after inhibition of NO synthesis
with 100 µmol/L NNLA in an endotoxin-treated and a control heart. In
the endotoxin-treated heart, there is an initial steep reduction of 4.0
mL/min per gram in coronary flow the first 3 minutes, with a more
sustained decrease in flow the following 20 minutes. In the control
heart, a gradual decline in coronary flow of only 0.5 mL/min per gram
is seen during the first 3 minutes after the administration of NNLA. As
early as 5 minutes after starting the NNLA administration, the
endotoxin-treated heart had reached approximately the same coronary
flow as the control heart. Fig 4 shows the steady state
situation 30 minutes after inhibition of NO synthesis. NNLA decreased
coronary flow by 8.5 mL/min per gram (57%) in the endotoxin group
(P<.05) and by 3 mL/min per gram (34%) in the control
group (P<.05). Thirty minutes after NNLA, coronary flow in
endotoxin-treated hearts (6.5±0.6 mL/min per gram) was not
significantly different from that in control hearts (6.1±0.6 mL/min
per gram). Effluent PO2 was reduced 35% to
299±50 mm Hg in endotoxin-treated hearts and 26% to 276±27 mm Hg
in control hearts. Oxygen consumption was significantly reduced in both
endotoxin-treated (32% reduction to 3.3±0.3 µmol/min per gram) and
control (18% reduction to 3.3±0.3 µmol/min per gram wet weight)
hearts. In hearts of dexamethasone-pretreated endotoxemic animals, NNLA
reduced coronary flow to 6.6±0.5 mL/min per gram and oxygen
consumption to 3.4±0.4 µmol/min per gram wet weight
(P<.05). No significant differences in coronary flow,
effluent PO2, and oxygen consumption
were present between the three groups receiving NNLA (Fig 4).
|
|
Effect of Perfusion Pressure After NNLA
Fig 2
shows the effect of different perfusion pressures on
coronary flow (Fig 2a), effluent PO2 (Fig 2b),
and oxygen consumption (Fig 2c) after inhibition of NO synthesis with
NNLA (100 µmol/L) in endotoxin-treated and control hearts. Relative
changes in coronary flow induced by NNLA depended on perfusion
pressure: they were larger at higher perfusion pressures in both
control and endotoxin-treated hearts (ANCOVA, P<.05). After
NNLA administration, no significant differences were present
between endotoxic and control hearts at all perfusion pressures.
Effect of NNLA on Surface NADH Fluorescence of Rat Hearts
Switching to perfusate containing NNLA at a perfusion pressure of
60 mm Hg resulted in the development of small areas of high
fluorescence in the endotoxin-treated hearts (Fig 5d),
which is indicative of local ischemia. The control hearts (Fig 5b)
remained without any sign of ischemia. The ischemic areas in the
endotoxic hearts were present at all perfusion pressures. They
disappeared after the addition of L-arginine, the natural
precursor of NO, or sodium nitroprusside, an exogenous NO donor,
indicating that the areas of ischemia are indeed caused by the action
of NO. In normal hearts, areas of ischemia appeared only when the
perfusion pressure was lowered to 20 and 30 mm Hg. The mean NADH
fluorescence was not significantly different between groups and was
raised only at a perfusion pressure of 20 mm Hg in both the
endotoxin-treated and control groups. NNLA did not significantly affect
mean NADH fluorescence in either group.
Effect of MB on Coronary Flow and Surface NADH Fluorescence
To study the effect of inhibiting soluble GC, the effector enzyme
of NO, we used MB (5 µmol/L) in control hearts (n=4) and
endotoxin-treated hearts (n=4). MB reduced coronary flow from 8.7±0.6
to 7.6±0.9 mL/min per gram wet weight (P=NS) in control
hearts and from 16.0±1.3 to 8.9±1.4 mL/min per gram wet weight
(P<.05) in endotoxin-treated hearts at a perfusion pressure
of 60 mm Hg. There was no significant difference in coronary flow
between control and endotoxin-treated hearts after the administration
of MB. However, MB produced areas of local ischemia in
endotoxin-treated hearts (Fig 6d) but not in the control
hearts (Fig 6b). The areas of ischemia remained present in
endotoxin-treated hearts at all perfusion pressures, whereas control
hearts showed signs of ischemia only at 20 and 30 mm Hg of perfusion
pressure.
|
MB in a dose of 10 µmol/L did not further reduce flow in control or endotoxin-treated hearts. Higher doses of MB (20 µmol/L) caused a paradoxical vasodilatation with a sustained increase in coronary flow, probably attributable to nonspecific toxic effects on cardiomyocytes.35
Effect of Direct Smooth Muscle Vasoconstriction With Vasopressin on
Surface NADH Fluorescence
It has been suggested that prevention of excess vasodilatation
might less likely cause ischemia and poor tissue perfusion than the use
of powerful vasoconstrictors.21 We investigated whether
the effect of reduction of coronary flow by a vasoconstrictor on local
tissue oxygenation was different from the reduction of flow by
inhibition of the NO pathway with NNLA or MB in control and
endotoxin-treated hearts. We used vasopressin, a direct smooth muscle
vasoconstrictor, in a concentration (1 nmol/L) that achieved a
reduction in coronary flow similar to that of 100 µmol/L NNLA at 60
mm Hg of perfusion pressure. At 60 mm Hg of perfusion pressure,
vasopressin produced areas of local ischemia in endotoxin-treated
hearts (Fig 7d) but not in the control group (Fig 7b).
With vasopressin, the areas of ischemia remained present in
endotoxin-treated hearts at all perfusion pressures, whereas control
hearts showed signs of ischemia only at 20 and 30 mm Hg of perfusion
pressure.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Myocardial circulation during septic shock is often characterized by an inappropriately high coronary flow.14 15 NO plays an important role in the regulation of myocardial flow.9 10 11 12 13 Therefore, we investigated the role of NO in the hyperdynamic changes of coronary flow in hearts of endotoxin-treated rats. The data in the present study indicate that these vascular changes are predominantly due to the vasodilatory action of NO. However, inhibition of the NO pathway can result in focal areas of ischemia in endotoxin-treated hearts, suggesting an imbalance of local oxygen supply to demand.
A rat model of endotoxemia using a sublethal low dose of endotoxin was
selected; this model produced a hyperdynamic coronary
circulation36 that is also seen in human
sepsis.14 15 Comparable to human sepsis, the model
resulted in raised temperature,36 reduced blood pressure,
and increased levels of plasma lactate37 and nitrate plus
nitrite. The 12 hours needed to establish this model provides
sufficient time for the inducible type of NO synthase to form,
estimated to take a lag phase of 4 to 6 hours.38
Pretreatment with dexamethasone, which inhibits only the inducible type
of NO synthase without affecting the constitutive
enzyme,7 8 inhibited the increase in coronary flow in this
model of endotoxemia. This suggests that the inducible type of NO
synthase is to a large extent responsible for the increase in coronary
flow. Dexamethasone, however, could not totally prevent the increase in
coronary flow, suggesting that the effect of dexamethasone is temporary
or that part of increased NO release is produced by the increased
activity of the constitutive NO synthase.39 40 Since
dexamethasone inhibits the LPS-induced synthesis and release of
interleukin-1 and tumor necrosis factor41 (both cytokines
stimulate the production of inducible NO synthase38 ), the
inhibitory effect could also be the result of diminished release of
these mediators in addition to direct inhibition of expression of the
enzyme.42
Not only the coronary vessels but also the myocardium itself has the capacity to express constitutive and inducible NO synthase.38 43 44 The constitutive form of NO synthase has been shown to be present in normal rat myocardium, and the inducible NO synthase is expressed after endotoxemia.38 Isolated myocytes of the rat express the inducible NO synthase only after stimulation with cytokines; this expression could be inhibited with dexamethasone.38 Increased release of NO by the inducible NO synthase within the cardiac myocytes themselves has been suggested to contribute to the reduced contractility of isolated guinea pig cardiac ventricular myocytes after endotoxemia.43 Human ventricular tissue of patients with dilated cardiomyopathy shows a significant activity of the inducible enzyme accompanied by a low activity of the constitutive NO synthase.44 This suggests that the inducible enzyme plays a pathological role in the myocardium, whereas the constitutive enzyme plays a more physiological role. To what extent the direct expression of NO synthase within cardiac myocytes itself contributed to the vascular relaxation in our model of endotoxemia remains to be established.
Our data indicate that reduction of excess coronary flow in endotoxemia, due to inhibition of the NO pathway with NNLA or MB, can cause local myocardial ischemia. In a recent study by Duncker and Bache,45 who used radioactive microspheres, NNLA was shown to exacerbate myocardial hypoperfusion during exercise in the presence of coronary stenosis in awake dogs. Administration of NG-monomethyl-L-arginine, another inhibitor of NO synthesis, has been reported to exacerbate global myocardial ischemia in vivo in a rabbit model of endotoxemia, as indicated by changes on the electrocardiogram.24 In the present study, foci of ischemia are indicated by areas of enhanced NADH fluorescence. This inhomogeneity of NADH fluorescence may be explained by a heterogeneously distributed blood flow throughout the heart,46 47 leading to an uneven distribution of ischemic areas in the myocardium during low coronary perfusion pressure or coronary flow restriction.48 The present study shows that heterogeneously distributed ischemia also exists after flow restriction by inhibition of the NO pathway in endotoxin-treated rat hearts but not in normal rat hearts. Since histological examination revealed no differences between groups and since overall parameters of coronary flow, effluent PO2, and oxygen consumption in endotoxin-treated hearts were not significantly different from those in control hearts after NNLA, the mismatch in local oxygen balance may reflect changes in local myocardial blood flow. The size of the ischemic areas, as revealed by NADH videofluorometry, are approximately the same size as those seen during near hypoxia in normal hearts. Using NADH videofluorometry, we have recently shown that such areas represent microcirculatory units at a capillary level that are consistently vulnerable to ischemia in the isolated rat heart.30 Our results suggest that endotoxemia promotes ischemia in these vulnerable areas.
Maldistribution of heterogeneous coronary blood flow has been demonstrated during endotoxic shock in vivo and may play a role in the development of depressed cardiac function.49 50 This idea is supported by the results of the present study. There could be several explanations for the appearance of ischemic foci during inhibition of the NO pathway. Regional maldistribution of coronary flow leading to underperfusion of myocardial tissue could have caused a local decrease in oxygen supply in endotoxin-treated hearts. No signs of ischemia, either local or global, were present in the isolated endotoxin-treated rat hearts when the NO pathway was not inhibited. This might indicate that maldistribution of coronary blood flow did not exist before flow limitation or that maldistribution of blood flow was compensated by increased overall coronary flow. Reducing coronary flow by inhibiting NO metabolism or direct smooth muscle vasoconstriction could have unmasked relatively underperfused (low-flow) areas in the endotoxin-treated hearts by causing myocardial ischemia. These ischemic areas probably represent the vulnerable units in the capillary network of the rat myocardium, which are the first to be compromised when oxygen supply becomes limited.30 An alternative explanation may be that oxygen demand is higher while distribution of flow remains the same. However, our results showed equal oxygen consumption for both groups after the inhibition of NO synthesis. Increasing coronary flow by restoring NO synthesis with L-arginine or providing exogenous NO with the NO donor nitroprusside restored perfusion in the ischemic areas in both cases. These findings support the idea that NO plays a role in maintaining organ perfusion.24 26
In general, it is thought that the constitutive NO synthase plays a role in maintaining organ perfusion, whereas the expression of the inducible form (as in sepsis and endotoxemia) leads to the production of excessive amounts of NO, resulting in vascular relaxation and tissue damage.24 The therapeutic use of NO inhibitors during sepsis should, therefore, be directed to inhibition of the inducible NO synthase. In the present study, we used inhibitors that affect constitutive and inducible NO synthase. The inhibition of only the inducible NO synthase might have prevented myocardial ischemia in endotoxin-treated hearts. However, to our knowledge, no selective inhibitors of only the inducible NO synthase are currently available. To prevent tissue hypoperfusion, total inhibition of NO synthesis combined with an exogenous NO donor could be helpful.24 In the present study, the exogenous NO donor sodium nitroprusside restored myocardial hypoperfusion when endogenous NO synthesis was totally inhibited with NNLA. Development of selective inhibitors of inducible NO synthase must be awaited; such selective inhibitors may be of special value in the future management of septic patients. For now, we suggest that the therapeutic use of nonselective NO inhibitors during sepsis must be done with caution and under careful cardiac monitoring.
The present study supports the notion that the massive coronary vasodilation seen in the isolated endotoxin-treated rat heart is caused by an increased release of NO. Inhibition of NO metabolism with NNLA or MB after endotoxemia reduced the coronary flow and caused areas of myocardial ischemia. Reducing coronary flow by direct vasoconstriction resulted in similar areas of myocardial ischemia, as did inhibition of the NO pathway. This finding suggests that the local balance between oxygen supply and oxygen demand in endotoxin-treated hearts is disturbed after flow restriction. Inhibition of NO synthesis during sepsis and endotoxemia has been reported to be accompanied by reductions in cardiac output21 22 23 24 25 27 and increased mortality.24 25 26 It could be that localized myocardial ischemia reported in the present study may have contributed to these deleterious effects. Conversely, it could be that the induction of NO synthase in the myocardium during endotoxemia may be a protective mechanism that prevents the development of local ischemia of malperfused cardiac tissue and that the inhibition of NO synthesis could be counterproductive.
|
Acknowledgments |
|---|
The authors wish to thank Dr J. van Amsterdam of the National Institute for Public Health and Environment for determination of nitrate plus nitrite concentration and Dr J.P. van der Sluijs for critical suggestions. The authors are also thankful for support by friends of the Rotterdam Blood Bank.
|
Footnotes |
|---|
Previously published as preliminary results in abstract form at the 22nd annual meeting of the International Society of Oxygen Transport to Tissue, 1994.
Received June 9, 1994; accepted November 21, 1994.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:456-469.
2. Groeneveld AB, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery. 1985;99:140-152.
3. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987;15:923-929. [Medline] [Order article via Infotrieve]
4. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49:186-196. [Medline] [Order article via Infotrieve]
5. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287. [Abstract]
6. Moncada S, Higgs EA. The L-arginine–nitric oxide pathway. N Engl J Med. 1993;30:2002-2012.
7. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun. 1990;173:541-547. [Medline] [Order article via Infotrieve]
8. Smith RE, Palmer RM, Moncada S. Coronary vasodilatation induced by endotoxin in the rabbit isolated perfused heart is nitric oxide-dependent and inhibited by dexamethasone. Br J Pharmacol. 1991;104:5-6. [Medline] [Order article via Infotrieve]
9. Amezcua JL, Palmer RMJ, de Souza BM, Moncada S. Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol. 1989;97:1119-1124. [Medline] [Order article via Infotrieve]
10.
Kelm M, Schrader J. Control of coronary vascular tone by
nitric oxide. Circ Res. 1990;66:1561-1575.
11.
Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of
inhibition of nitric oxide synthesis on epicardial caliber and coronary
blood flow in humans. Circulation. 1993;88:43-54.
12.
Amrani M, O'Shea J, Allen NJ, Harding SE, Jayakumar J,
Pepper
JR, Moncada S, Yacoub MH. Role of basal release of nitric oxide on
coronary flow and mechanical performance of the isolated rat heart.
J Physiol (Lond). 1992;456:681-687.
13. Chu A, Chambers DE, Lin CC, Kuehl WD, Palmer RM. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest. 1991;87:1964-1968.
14.
Cunnion RE, Schaer GL, Parker MM, Natanson C, Parillo JE. The
coronary circulation in human septic shock.
Circulation. 1986;73:637-644.
15.
Dhainaut JF, Huygebaert MF, Monsalier JF, Lefevre G,
Ava-Santucci J, Brunet F, Villemant D, Carli A, Raichvarg D. Coronary
hemodynamics and myocardial metabolism of lactate, free fatty acids,
glucose, and ketones in patients with septic shock.
Circulation. 1987;75:533-541.
16. Lang CH, Bagby GJ, Ferguson JL, Spitzer JJ. Cardiac output and redistribution of blood flow in hypermetabolic sepsis. Am J Physiol. 1983;246:R331-R337.
17. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium dependent relaxation. Br J Pharmacol. 1989;96:418-424. [Medline] [Order article via Infotrieve]
18. Moore PK, al-Swayeh OA, Chong NWS, Evans RA, Gibson A. L-NG-Nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilation in vitro. Br J Pharmacol. 1990;99:408-412. [Medline] [Order article via Infotrieve]
19.
Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective
blockade of endothelium dependent and glyceryl trinitrate-induced
relaxation by hemoglobin and by methylene blue in the rabbit aorta.
J Pharmacol Exp Ther. 1985;232:708-716.
20. Schilling J, Cakmakci M. Bättig U, Geroulanos S. A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med. 1993;19:227-231. [Medline] [Order article via Infotrieve]
21. Petros A, Bennet D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-1558. [Medline] [Order article via Infotrieve]
22.
Petros A, Lamb G, Leone A, Moncada S, Bennet D, Vallance P.
Effects of a nitric oxide synthase inhibitor in humans with septic
shock. Cardiovasc Res. 1994;28:34-39.
23. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempé JD. Methylene blue increases systemic vascular resistance in human septic shock. Intensive Care Med. 1992;18:309-311.[Medline] [Order article via Infotrieve]
24.
Wright CE, Rees DD, Moncada S. Protective and pathological
roles of nitric oxide in endotoxin shock. Cardiovasc Res. 1992;26:48-57.
25.
Cobb JP, Natanson C, Hoffman WD, Lodato RF, Banks S, Koev CA,
Solomon MA, Elin RJ, Hosseini JM, Danner RL.
N-Amino-L-arginine, an inhibitor of nitric oxide
synthase, raises vascular resistance but increases mortality rates in
awake canines challenged with endotoxin. J Exp Med. 1992;176:1175-1182.
26. Nava E, Palmer RM, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet. 1991;338:1555-1557. [Medline] [Order article via Infotrieve]
27. Klabunde RE, Ritger RC. NG-Monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun. 1991;178:1135-1140. [Medline] [Order article via Infotrieve]
28. Hotchkiss RS, Karl IE, Parker JL, Adams HR. Letter to the editor. Lancet. 1992;339:434-435.
29. Chance B. Pyridine nucleotide as an indicator of the oxygen requirements for energy-linked functions of mitochondria. Circ Res. 1976;38(suppl I):I-31-I-38.
30.
Ince C, Ashruf JF, Avontuur JA, Wieringa PA, Spaan JA,
Bruining HA. Heterogeneity of the hypoxic state in rat heart is
determined at capillary level. Am J Physiol. 1993;264:H294-H301.
31. Gawehn K, Bergmeyer HU. Lactate. In: Bergmeyer, HU, ed. Methods of Enzymatic Analysis. New York, NY: Academic Press Inc; 1974:1492-1493.
32. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138. [Medline] [Order article via Infotrieve]
33.
Gregg DE. Effect of coronary perfusion pressure or coronary
flow on oxygen usage of the myocardium. Circ Res. 1963;13:497-500.
34.
Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL,
Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle
relaxation by organic nitrates, nitrites, nitroprusside and nitric
oxide: evidence for the involvement of S-nitrosothiols as active
intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
35. Baydoun AR, Peers SH, Cirino G, Woodward B. Vasodilator action of endothelin-1 in the perfused rat heart. J Cardiovasc Pharmacol. 1990;15:759-763. [Medline] [Order article via Infotrieve]
36.
Rumsey WL, Kilpatrick L, Wilson DF, Erecinska M. Myocardial
metabolism and coronary flow: effects of endotoxemia. Am J
Physiol. 1988;255:H1295-H1304.
37. Kilpatrick-Smith L, Yoder MC, Polin RA, Douglas SD, Erecinska M. Endotoxin-induced changes in nitrogen metabolism. Res Commun Chem Pathol Pharmacol. 1986;53:381-398. [Medline] [Order article via Infotrieve]
38. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575-580. [Medline] [Order article via Infotrieve]
39. Baydoun AR, Foale RD, Mann GE. Bacterial endotoxin rapidly stimulates prolonged endothelium-dependent vasodilatation in the rat isolated perfused heart. Br J Pharmacol. 1993;109:987-991. [Medline] [Order article via Infotrieve]
40. Szabo C, Mitchell JA, Thiemermann C, Vane JR. Nitric-oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol. 1993;108:786-792. [Medline] [Order article via Infotrieve]
41. Zuckermann SH, Shellhaas J, Butler LD. Differential regulation of lipopolysaccharide-induced interleukin-1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol. 1989;19:301-305. [Medline] [Order article via Infotrieve]
42.
Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA,
Wang SC, Simmons RL, Billiar TR. Cytokines, endotoxin, and
glucocorticoids regulate the expression of inducible nitric oxide
synthase in hepatocytes. Proc Natl Acad Sci U S A. 1993;90:522-526.
43. Brady JB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol. 1992;263(Heart Circ Physiol 32):H1963-H1966.
44. De Belder AJ, Radomski MR, Why HJ, Richardson PJ, Bucknall CA, Salas E, Martin JF, Moncada S. Nitric oxide synthase activities in human myocardium. Lancet. 1993;341:84-85. [Medline] [Order article via Infotrieve]
45.
Duncker DJ, Bache RJ. Inhibition of nitric oxide production
aggravates myocardial hypoperfusion during exercise in the presence of
a coronary artery stenosis. Circ Res. 1994;74:629-640.
46.
King RB, Bassingthwaigthe JB, Hales JR, Rowell LB. Stability
of heterogeneity of myocardial blood flow in normal awake baboons.
Circ Res. 1985;57:285-295.
47. Conway RS, Weiss H. Dependence of spatial heterogeneity of myocardial blood flow on mean blood flow rate in the rabbit heart. Cardiovasc Res. 1985;19:160-168. [Medline] [Order article via Infotrieve]
48.
Steenbergen C, Deleeuw G, Barlow C, Chance B, Williamson JR.
Heterogeneity of the hypoxic state in perfused rat heart.
Circ Res. 1977;41:606-615.
49.
Groeneveldt AB, van Lambalgen AA, van den Bos GC, Bronsveld W,
Nauta JP, Lambertus GT. Maldistribution of heterogeneous coronary blood
flow during canine endotoxin shock. Cardiovasc Res. 1991;25:80-88.
50. Goldfarb RD, Nightingale LM, Kish P, Weber PB, Loegering DJ. Left ventricular function during lethal and sublethal endotoxemia in the swine. Am J Physiol. 1986;251:H364-H373.
This article has been cited by other articles:
 |
|
 |
|
  K. Katada, A. Bihari, A. Badhwar, N. Yoshida, T. Yoshikawa, R. F. Potter, and G. Cepinskas Hindlimb Ischemia/Reperfusion-Induced Remote Injury to the Small Intestine: Role of Inducible Nitric-Oxide Synthase-Derived Nitric Oxide J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 919 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Bateman, C. Tokunaga, T. Kareco, D. R. Dorscheid, and K. R. Walley Myocardial hypoxia-inducible HIF-1{alpha}, VEGF, and GLUT1 gene expression is associated with microvascular and ICAM-1 heterogeneity during endotoxemia Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H448 - H456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Kane, C.-F. Lam, F. O'Cochlain, D. M. Hodgson, S. Reyes, X.-K. Liu, T. Miki, S. Seino, Z. S. Katusic, and A. Terzic Gene knockout of the KCNJ8-encoded Kir6.1 KATP channel imparts fatal susceptibility to endotoxemia FASEB J, November 1, 2006; 20(13): 2271 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Eerbeek, E. G. Mik, C. J. Zuurbier, M. v. t Loo, C. Donkersloot, and C. Ince Ratiometric intracellular calcium imaging in the isolated beating rat heart using indo-1 fluorescence J Appl Physiol, December 1, 2004; 97(6): 2042 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Paz, I. Frolkis, D. Pevni, I. Shapira, Y. Yuhas, A. Iaina, Y. Wollman, T. Chernichovski, N. Nesher, C. Locker, et al. Effect of tumor necrosis Factor-Alphaon endothelial and inducible nitric oxidesynthase messenger ribonucleic acidexpression and nitric oxide synthesisin ischemic and nonischemic isolated rat heart J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1299 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Y. Poon, E. Raharjo, K. D. Patel, S. Tavener, and P. Kubes Complexity of Inducible Nitric Oxide Synthase: Cellular Source Determines Benefit Versus Toxicity Circulation, September 2, 2003; 108(9): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. VINCENT, H. ZHANG, C. SZABO, and J.-C. PREISER Effects of Nitric Oxide in Septic Shock Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1781 - 1785. [Abstract] [Full Text]
|
|
|
|
|
|
U. Sibelius, U. Grandel, M. Buerke, D. Mueller, L. Kiss, H.-J. Kraemer, R. Braun-Dullaeus, W. Haberbosch, W. Seeger, and F. Grimminger Staphylococcal {alpha}-Toxin Provokes Coronary Vasoconstriction and Loss in Myocardial Contractility in Perfused Rat Hearts : Role of Thromboxane Generation Circulation, January 4, 2000; 101(1): 78 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Ashruf, C. Ince, and H. A. Bruining Regional ischemia in hypertrophic Langendorff-perfused rat hearts Am J Physiol Heart Circ Physiol, October 1, 1999; 277(4): H1532 - H1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A.M Avontuur, H. A Bruining, and C. Ince Nitric oxide causes dysfunction of coronary autoregulation in endotoxemic rats Cardiovasc Res, August 1, 1997; 35(2): 368 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. ROSSELET, F. FEIHL, M. MARKERT, A. GNAEGI, C. PERRET, and L. LIAUDET Selective iNOS Inhibition Is Superior to Norepinephrine in the Treatment of Rat Endotoxic Shock Am. J. Respir. Crit. Care Med., January 1, 1997; 157(1): 162 - 170. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||